Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Return on Sales
Return on Investment
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
The financial performance from 2014 to 2018 is characterized by exceptionally high gross margins and a significant acceleration in equity returns, despite some volatility in operating and net profitability during the mid-period.
- Gross Profit Margin
- A consistently high and stable margin is observed, remaining above 94% throughout the five-year period. The margin peaked at 96.45% in 2017, indicating a strong ability to maintain pricing power and manage direct production costs effectively.
- Operating and Net Profit Margins
- Both metrics experienced a notable contraction in 2015, with the operating margin falling to 24.61% and the net margin dropping to 17.49%. However, a recovery trend followed, with the net profit margin returning to its 2014 levels by 2018, reaching 26.51%.
- Return on Equity (ROE)
- A substantial upward trajectory is evident in the return on equity. After fluctuating between 27% and 30% from 2014 to 2016, ROE grew aggressively to 42.48% in 2017 and reached a peak of 65.67% in 2018, suggesting a significant increase in the efficiency of generating profits from shareholders' equity.
- Return on Assets (ROA)
- The return on assets followed a U-shaped pattern, declining from 11.53% in 2014 to a low of 5.92% in 2015. A subsequent recovery occurred over the following three years, ending the period at 11.40% in 2018, which aligns closely with the initial 2014 performance.
Overall, the divergence between the stable ROA and the rapidly increasing ROE toward the end of the period suggests a change in the capital structure or an increase in financial leverage to amplify returns to shareholders.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Gross Profit Margin
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Gross profit | 14,678) | 12,512) | 10,747) | 8,741) | 7,178) | |
| Net product sales | 15,265) | 12,973) | 11,185) | 9,161) | 7,564) | |
| Profitability Ratio | ||||||
| Gross profit margin1 | 96.15% | 96.45% | 96.08% | 95.41% | 94.90% | |
| Benchmarks | ||||||
| Gross Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Gross profit margin = 100 × Gross profit ÷ Net product sales
= 100 × 14,678 ÷ 15,265 = 96.15%
2 Click competitor name to see calculations.
The financial performance between 2014 and 2018 is characterized by sustained growth in both top-line revenue and absolute gross profit, while maintaining an exceptionally high and stable margin of profitability.
- Net Product Sales Trend
- A consistent upward trajectory is observed in net product sales, which increased from 7,564 million US dollars in 2014 to 15,265 million US dollars by 2018. This represents a steady expansion of revenue over the five-year period.
- Gross Profit Growth
- Gross profit scaled in tandem with sales, rising from 7,178 million US dollars in 2014 to 14,678 million US dollars in 2018. The growth in absolute profit demonstrates a strong ability to convert increased sales into gross earnings.
- Gross Profit Margin Stability
- The gross profit margin remained remarkably high throughout the period, starting at 94.90% in 2014 and peaking at 96.45% in 2017. Although a slight decrease to 96.15% was noted in 2018, the margin's overall stability indicates that the cost of goods sold has remained a negligible fraction of net sales, reflecting strong pricing power and efficient cost management.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Operating Profit Margin
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Operating income | 5,191) | 4,707) | 3,167) | 2,255) | 2,519) | |
| Net product sales | 15,265) | 12,973) | 11,185) | 9,161) | 7,564) | |
| Profitability Ratio | ||||||
| Operating profit margin1 | 34.01% | 36.28% | 28.31% | 24.61% | 33.30% | |
| Benchmarks | ||||||
| Operating Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Operating profit margin = 100 × Operating income ÷ Net product sales
= 100 × 5,191 ÷ 15,265 = 34.01%
2 Click competitor name to see calculations.
Analysis of the financial performance between 2014 and 2018 reveals a consistent growth trajectory in top-line revenue, contrasted by fluctuations in operational efficiency and profitability margins.
- Net Product Sales Trend
- A steady and uninterrupted increase in net product sales is observed throughout the five-year period. Revenue grew from 7,564 million US$ in 2014 to 15,265 million US$ in 2018, representing a significant expansion in market reach or product demand.
- Operating Income Volatility
- Operating income demonstrated a general upward trend, increasing from 2,519 million US$ in 2014 to 5,191 million US$ in 2018. However, a contraction occurred in 2015, where income dropped to 2,255 million US$, before recovering strongly through 2017 and 2018.
- Operating Profit Margin Analysis
- The operating profit margin exhibited considerable variability. A notable decline is evident in 2015, with the margin falling to 24.61% from 33.30% in 2014. This was followed by a period of recovery, peaking at 36.28% in 2017, before a slight moderation to 34.01% in 2018.
- Correlation Between Revenue and Efficiency
- While net product sales grew linearly, the operating profit margin did not move in direct proportion to revenue. The dip in 2015 suggests a temporary increase in operating expenses relative to sales, while the subsequent rise in margin through 2017 indicates a period of enhanced operational leverage and cost management.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Net Profit Margin
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income | 4,046) | 2,940) | 1,999) | 1,602) | 2,000) | |
| Net product sales | 15,265) | 12,973) | 11,185) | 9,161) | 7,564) | |
| Profitability Ratio | ||||||
| Net profit margin1 | 26.51% | 22.66% | 17.87% | 17.49% | 26.44% | |
| Benchmarks | ||||||
| Net Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
Net profit margin = 100 × Net income ÷ Net product sales
= 100 × 4,046 ÷ 15,265 = 26.51%
2 Click competitor name to see calculations.
The financial performance between 2014 and 2018 is characterized by consistent revenue growth accompanied by a period of profitability volatility that ultimately recovered to its initial levels.
- Revenue Growth Trend
- Net product sales exhibited an uninterrupted upward trajectory over the five-year period. Sales increased from US$ 7,564 million in 2014 to US$ 15,265 million by 2018, representing a substantial expansion of the top line.
- Net Income Fluctuations
- Net income did not follow the linear growth of sales. A notable decline occurred in 2015, where income dropped to US$ 1,602 million from US$ 2,000 million in 2014. Following this dip, net income entered a phase of accelerated growth, rising consistently to reach US$ 4,046 million by the end of 2018.
- Net Profit Margin Analysis
- The net profit margin experienced a V-shaped trend. The margin contracted sharply from 26.44% in 2014 to a low of 17.49% in 2015. Stability was observed in 2016 at 17.87%, followed by a strong recovery in 2017 (22.66%) and a return to peak efficiency in 2018, closing at 26.51%.
- Operational Efficiency Insight
- The divergence between rising sales and falling net income in 2015 suggests a period of increased operational costs or non-recurring expenses. However, the subsequent margin expansion indicates that the company successfully scaled its operations, as the rate of net income growth surpassed the rate of sales growth from 2016 through 2018.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Return on Equity (ROE)
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income | 4,046) | 2,940) | 1,999) | 1,602) | 2,000) | |
| Stockholders’ equity | 6,161) | 6,921) | 6,599) | 5,919) | 6,525) | |
| Profitability Ratio | ||||||
| ROE1 | 65.67% | 42.48% | 30.29% | 27.07% | 30.65% | |
| Benchmarks | ||||||
| ROE, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
ROE = 100 × Net income ÷ Stockholders’ equity
= 100 × 4,046 ÷ 6,161 = 65.67%
2 Click competitor name to see calculations.
An analysis of the financial performance from 2014 to 2018 reveals a significant acceleration in profitability and capital efficiency. While the period began with a brief contraction in 2015, a strong upward trajectory in net income coupled with strategic shifts in equity levels resulted in a substantial increase in the return generated for shareholders.
- Net Income Trends
- Net income experienced a temporary decline in 2015, dropping to US$ 1,602 million from US$ 2,000 million in 2014. However, a period of consistent and aggressive growth followed, with net income rising to US$ 1,999 million in 2016, US$ 2,940 million in 2017, and peaking at US$ 4,046 million by the end of 2018. This represents a total increase of approximately 102% from the 2015 low to the 2018 high.
- Stockholders’ Equity Dynamics
- The equity base exhibited fluctuations throughout the five-year period. After a decrease to US$ 5,919 million in 2015, equity grew steadily to a peak of US$ 6,921 million in 2017. A notable contraction occurred in 2018, where equity fell to US$ 6,161 million. This reduction in the equity base during a year of record net income served as a primary driver for the expansion of profitability ratios.
- Return on Equity (ROE) Acceleration
- The ROE remained relatively stable between 2014 and 2016, ranging from 27.07% to 30.65%. Starting in 2017, a sharp upward trend emerged, with ROE climbing to 42.48% and reaching a peak of 65.67% in 2018. The dramatic rise in ROE in the final two years is attributable to the simultaneous increase in net income and the reduction in total stockholders' equity, indicating a heightened efficiency in utilizing shareholder capital to generate profit.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Return on Assets (ROA)
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income | 4,046) | 2,940) | 1,999) | 1,602) | 2,000) | |
| Total assets | 35,480) | 30,141) | 28,086) | 27,053) | 17,340) | |
| Profitability Ratio | ||||||
| ROA1 | 11.40% | 9.75% | 7.12% | 5.92% | 11.53% | |
| Benchmarks | ||||||
| ROA, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 2018 Calculation
ROA = 100 × Net income ÷ Total assets
= 100 × 4,046 ÷ 35,480 = 11.40%
2 Click competitor name to see calculations.
The Return on Assets (ROA) exhibited a V-shaped trajectory between 2014 and 2018, characterized by an initial sharp contraction followed by a sustained period of recovery. While the ratio nearly returned to its 2014 level by the end of the period, the underlying components of the ratio shifted significantly.
- Net Income Trends
- Earnings experienced a decline in 2015, dropping to 1,602 million from 2,000 million in 2014. Following this dip, a strong upward trend was established, with net income increasing annually to reach 4,046 million by December 31, 2018, representing more than a twofold increase from the 2015 low.
- Total Asset Expansion
- The asset base underwent substantial growth throughout the analyzed period. A significant expansion occurred between 2014 and 2015, where assets rose from 17,340 million to 27,053 million. This growth continued at a more moderate pace in subsequent years, culminating in a total asset value of 35,480 million by 2018.
- ROA Performance and Asset Efficiency
- The ROA fell sharply from 11.53% in 2014 to 5.92% in 2015, a result of simultaneous earnings contraction and rapid asset accumulation. From 2016 onward, a consistent recovery was observed, with the ratio climbing to 7.12%, then 9.75%, and finally 11.40% in 2018. The recovery indicates that net income growth began to outpace the growth of the asset base, effectively restoring the organization's ability to generate profit from its expanded resources.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?